Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse
Bidra et al.,
Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using..,
Journal of Prosthodontics, doi:10.1111/jopr.13209 (In Vitro)
Bidra et al., 8 Jun 2020, peer-reviewed, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Rapid In-Vitro Inactivation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine
Oral Antiseptic Rinse
Avinash S. Bidra , BDS, MS, FACP ,1 Jesse S Pelletier , MD, FACS,2 Jonna B Westover , PhD,3
Samantha Frank , MD,4 Seth M Brown , MD, MBA,4,5 & Belachew Tessema , MD, FACS4,5
1
Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT
Ocean Ophthalmology Group, Miami, FL
3
The Institute for Antiviral Research at Utah State University, Logan, UT
4
Department of Otolaryngology, University of Connecticut Health Center, Farmington, CT
5
ProHealth Physicians Ear, Nose and Throat, Farmington, CT
2
Keywords
SARS-CoV-2; corona virus; povidone-iodine;
dental safety; oral rinse.
Correspondence
Avinash Bidra, Department. of Reconstructive
Sciences, University of Connecticut Health
Center, 263 Farmington Ave., L7039,
Farmington, CT 06030.
E-mail: avinashbidra@yahoo.com
The authors deny any conflicts of interest.
Accepted June 4, 2020
doi: 10.1111/jopr.13209
Abstract
Purpose: To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 (‘corona
virus’) to mitigate the risk and transmission of the virus in the dental practice.
Materials and Methods: The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic
solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient.
The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media
without any virus was added to 2 tubes of the compounds to serve as toxicity and
neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and
water only as a negative control. The test solutions and virus were incubated at room
temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was
then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal
bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was
quantified by standard end-point dilution assay and the log reduction value (LRV) of
each compound compared to the negative (water) control was calculated.
Results: PVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%,
completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol
control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of
contact, but was able to inactivate the virus at 30 seconds of contact.
Conclusions: PVP-I oral antiseptic preparations rapidly inactivated SARS-CoV2 virus in vitro. The viricidal activity was present at the lowest concentration of
0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding
can justify the use of preprocedural oral rinsing with PVP-I (for patients and health
care providers) may be useful as an adjunct to personal protective equipment, for
dental and surgical specialties during the COVID-19 pandemic.
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2 the virus resulting in the corona virus disease 2019,
COVID-19) is a novel coronavirus in the same family as the
severe acute respiratory syndrome (SARS) and middle east
respiratory syndrome (MERS) viruses that emerged in local
outbreaks in 2003 and 2015. From the first cases recognized
in late December 2019 by health care workers in China,
it has rapidly spread across the globe.1 The..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit